Disruption of Protein Kinase A Interaction with A-kinase-anchoring Proteins in the Heart in Vivo: EFFECTS ON CARDIAC CONTRACTILITY, PROTEIN KINASE A PHOSPHORYLATION, AND TROPONIN I PROTEOLYSIS

• Published in: The Journal of biological chemistry 2009-01, Vol.284 (3), p.1583-1592
• Main Authors: McConnell, Bradley K, Popovic, Zoran, Mal, Niladri, Lee, Kwangdeok, Bautista, James, Forudi, Farhad, Schwartzman, Raul, Jin, J.-P, Penn, Marc, Bond, Meredith
• Format: Article
• Language: English
• Subjects: A Kinase Anchor Proteins - genetics; A Kinase Anchor Proteins - metabolism; Adenoviridae; Animals; Calcium-Binding Proteins - genetics; Calcium-Binding Proteins - metabolism; Cardiotonic Agents - pharmacology; Cyclic AMP-Dependent Protein Kinase Type II - genetics; Cyclic AMP-Dependent Protein Kinase Type II - metabolism; Gene Expression; Isoproterenol - pharmacology; Male; Mechanisms of Signal Transduction; Mice; Myocardial Contraction - drug effects; Myocardial Contraction - physiology; Myocardium - metabolism; Peptides - genetics; Peptides - metabolism; Phosphorylation - drug effects; Phosphorylation - physiology; Rats; Ryanodine Receptor Calcium Release Channel - genetics; Ryanodine Receptor Calcium Release Channel - metabolism; Stroke Volume - drug effects; Stroke Volume - physiology; Transduction, Genetic; Troponin I - genetics; Troponin I - metabolism
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M806321200

Protein kinase A (PKA)-dependent phosphorylation is regulated by targeting of PKA to its substrate as a result of binding of regulatory subunit, R, to A-kinase-anchoring proteins (AKAPs). We investigated the effects of disrupting PKA targeting to AKAPs in the heart by expressing the 24-amino acid regulatory subunit RII-binding peptide, Ht31, its inactive analog, Ht31P, or enhanced green fluorescent protein by adenoviral gene transfer into rat hearts in vivo. Ht31 expression resulted in loss of the striated staining pattern of type II PKA (RII), indicating loss of PKA from binding sites on endogenous AKAPs. In the absence of isoproterenol stimulation, Ht31-expressing hearts had decreased +dP/dtmax and -dP/dtmin but no change in left ventricular ejection fraction or stroke volume and decreased end diastolic pressure versus controls. This suggests that cardiac output is unchanged despite decreased +dP/dt and -dP/dt. There was also no difference in PKA phosphorylation of cardiac troponin I (cTnI), phospholamban, or ryanodine receptor (RyR₂). Upon isoproterenol infusion, +dP/dtmax and -dP/dtmin did not differ between Ht31 hearts and controls. At higher doses of isoproterenol, left ventricular ejection fraction and stroke volume increased versus isoproterenol-stimulated controls. This occurred in the context of decreased PKA phosphorylation of cTnI, RyR₂, and phospholamban versus controls. We previously showed that expression of N-terminal-cleaved cTnI (cTnI-ND) in transgenic mice improves cardiac function. Increased cTnI N-terminal truncation was also observed in Ht31-expressing hearts versus controls. Increased cTnI-ND may help compensate for reduced PKA phosphorylation as occurs in heart failure.